ArticleFrontiers in psychology2022
The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.
Article in Frontiers in psychology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07737990 (Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Set and Setting for Psychedelic Harm Reduction.Current topics in behavioral neurosciences · 2026Review
- Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework.Frontiers in psychiatry · 2026Article
- From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).Scientific reports · 2025Article
- Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of Competence.Psychedelic medicine (New Rochelle, N.Y.) · 2024Review
- Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.BMC psychiatry · 2024Article
- 6-Fold path to self-forgiveness: an interdisciplinary model for the treatment of moral injury with intervention strategies for clinicians.Frontiers in psychology · 2024Article
- Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.Journal of psychopharmacology (Oxford, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we describe the development and initial validation of two psychometric scales for measuring psychedelic integration. Psychedelic integration refers to the post-acute period of time following psychedelic drug administration. We created the Integration Engagement Scale (IES) to capture positive behavioral engagement with integration and the Experienced Integration Scale (EIS) to capture internal aspects of feeling integrated. These scales were developed to measure post-acute psychedelic administration dynamics in order to inform the creation of enhanced integration support and to help refine a general conceptual understanding of the construct of psychedelic integration. The scales are brief and face valid instruments designed for practical use in applied and research settings. Scale items were generated and refined using the Iterative Process Model of scale development, with input from psychedelics experts and clinicians. Content validity, internal structure, and reliability were assessed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.